Ali Behbahani

Filings by Ali Behbahani span 18 companies, the busiest being Black Diamond Therapeutics, Inc., Arcellx, Inc. and CRISPR Therapeutics AG. The record holds 58 filings, for trades running from 7 June 2021 to 18 September 2026.

The open-market side counts 4 purchases for €10.1M alongside 5 sales for €922k. The amount is not disclosed for 2 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 29 share grants and 2 option exercises. Since January 2026: no purchases and 1 sale on the market.

Half of the purchases are above €4.6M and half below. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 21 September 2026, reports an option exercise of €366k in CRISPR Therapeutics AG. The last insider purchase was made public on 19 July 2023, 1,187 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.